

# Jorge Di Paola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3095014/publications.pdf>

Version: 2024-02-01

81  
papers

2,850  
citations

236925

25  
h-index

182427

51  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3624  
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. <i>Nature Genetics</i> , 2015, 47, 535-538.	21.4	274
2	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 280-300.	5.2	246
3	Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. <i>Nature Genetics</i> , 2011, 43, 738-740.	21.4	239
4	TNF- $\alpha$ -driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. <i>Blood</i> , 2019, 134, 727-740.	1.4	199
5	Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. <i>Blood</i> , 2008, 111, 1257-1265.	1.4	189
6	Factor XIII activity mediates red blood cell retention in venous thrombi. <i>Journal of Clinical Investigation</i> , 2014, 124, 3590-3600.	8.2	165
7	Diagnostic approach to von Willebrand disease. <i>Blood</i> , 2015, 125, 2029-2037.	1.4	148
8	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. <i>Blood</i> , 2017, 130, 2344-2353.	1.4	98
9	Platelet clearance via shear-induced unfolding of a membrane mechanoreceptor. <i>Nature Communications</i> , 2016, 7, 12863.	12.8	87
10	The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. <i>Blood</i> , 2005, 105, 518-525.	1.4	83
11	Significant gynecological bleeding in women with low von Willebrand factor levels. <i>Blood Advances</i> , 2018, 2, 1784-1791.	5.2	79
12	Glanzmann thrombasthenia: genetic basis and clinical correlates. <i>Haematologica</i> , 2020, 105, 888-894.	3.5	75
13	Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. <i>Thrombosis Research</i> , 2015, 136, 13-19.	1.7	59
14	Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 276-282.	1.0	53
15	A local and global sensitivity analysis of a mathematical model of coagulation and platelet deposition under flow. <i>PLoS ONE</i> , 2018, 13, e0200917.	2.5	45
16	ETV6-related thrombocytopenia and leukemia predisposition. <i>Blood</i> , 2019, 134, 663-667.	1.4	45
17	Role of FcR $\beta$ 3 and factor XIIIa in coated platelet formation. <i>Blood</i> , 2005, 106, 4146-4151.	1.4	43
18	GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis. <i>Frontiers in Medicine</i> , 2018, 5, 137.	2.6	36

#	ARTICLE	IF	CITATIONS
19	Turbulent Flow Promotes Cleavage of VWF (von Willebrand Factor) by ADAMTS13 (A Disintegrin and) Tj ETQq1 1 0.784314 rgBT /Over Vascular Biology, 2019, 39, 1831-1842.	2.4	36
20	Hemostasis vs. homeostasis: Platelets are essential for preserving vascular barrier function in the absence of injury or inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24316-24325.	7.1	33
21	Recombinant Factor IX for Clinical and Research Use. Seminars in Thrombosis and Hemostasis, 2010, 36, 498-509.	2.7	32
22	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	1.4	32
23	Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. Haematologica, 2020, 105, 585-597.	3.5	32
24	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
25	Thrombocytopenias Due to Gray Platelet Syndrome or <i>ITGA2B</i> Mutations. Seminars in Thrombosis and Hemostasis, 2011, 37, 690-697.	2.7	29
26	<i>ITGA2B</i> mutations and bleeding in patients with gray platelet syndrome. Platelets, 2018, 29, 632-635.	2.3	29
27	Homozygosity mapping with SNP arrays confirms 3p21 as a recessive locus for gray platelet syndrome and narrows the interval significantly. Blood, 2011, 117, 3430-3434.	1.4	25
28	Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood, 2002, 100, 2839-2844.	1.4	22
29	Tissue Factor Signals Airway Epithelial Basal Cell Survival via Coagulation and Protease-Activated Receptor Isoforms 1 and 2. American Journal of Respiratory Cell and Molecular Biology, 2013, 48, 94-104.	2.9	21
30	Platelet activation contributes to hypoxia-induced inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L413-L421.	2.9	21
31	Specifications of the variant curation guidelines for <i>ITGA2B</i> / <i>ITGB3</i> : ClinGen Platelet Disorder Variant Curation Panel. Blood Advances, 2021, 5, 414-431.	5.2	19
32	Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood, 2015, 126, 262-269.	1.4	16
33	Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine-restricted diet or enzyme replacement therapy. FASEB Journal, 2019, 33, 12477-12486.	0.5	16
34	Recovery and analysis of transcriptome subsets from pooled single-cell RNA-seq libraries. Nucleic Acids Research, 2019, 47, e20-e20.	14.5	16
35	Chitinase 3-like 1 promotes intrahepatic activation of coagulation through induction of tissue factor in mice. Hepatology, 2018, 67, 2384-2396.	7.3	15
36	ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes. JCI Insight, 2020, 5, .	5.0	15

#	ARTICLE	IF	CITATIONS
37	Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: Implications for identifying coagulopathic mechanisms in humans. <i>Thrombosis and Haemostasis</i> , 2012, 108, 516-526.	3.4	14
38	Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. <i>Scientific Reports</i> , 2017, 7, 4275.	3.3	14
39	Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in Mice. <i>PLoS ONE</i> , 2016, 11, e0150852.	2.5	13
40	Loss of fibrinogen in zebrafish results in an asymptomatic embryonic hemostatic defect and synthetic lethality with thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 607-617.	3.8	12
41	von Willebrand Disease. <i>Pediatric Clinics of North America</i> , 2018, 65, 527-541.	1.8	11
42	Platelet $\alpha$ -granules are required for occlusive high-shear-rate thrombosis. <i>Blood Advances</i> , 2020, 4, 3258-3267.	5.2	11
43	Deep Venous Thrombosis and Turner Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 272.	0.6	10
44	Effects of anti- $\alpha$ 2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 380-389.	2.3	10
45	TNF- $\alpha$ Driven Inflammation and Mitochondrial Dysfunction Characterize the Platelet Hyperreactivity of Aging and Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2018, 132, 1134-1134.	1.4	10
46	Isotopically nonstationary $^{13}\text{C}$ metabolic flux analysis in resting and activated human platelets. <i>Metabolic Engineering</i> , 2022, 69, 313-322.	7.0	10
47	Genetics of inherited thrombocytopenias. <i>Blood</i> , 2022, 139, 3264-3277.	1.4	10
48	A novel mutation in PLP1 causes severe hereditary spastic paraplegia type 2. <i>Gene</i> , 2014, 533, 447-450.	2.2	9
49	Pathologic Shear and Elongation Rates Do Not Cause Cleavage of Von Willebrand Factor by ADAMTS13 in a Purified System. <i>Cellular and Molecular Bioengineering</i> , 2020, 13, 379-390.	2.1	9
50	Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels. <i>Blood</i> , 2022, 139, 2240-2251.	1.4	9
51	von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene. <i>Blood</i> , 2021, 137, 3277-3283.	1.4	8
52	New developments in the treatment of pediatric hemophilia and bleeding disorders. <i>Current Opinion in Pediatrics</i> , 2013, 25, 23-30.	2.0	6
53	Tamoxifen Suppresses Platelet Activation-Supported Angiogenesis and Metastasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 611-612.	2.4	6
54	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. <i>Blood Advances</i> , 2021, 5, 5023-5031.	5.2	6

#	ARTICLE	IF	CITATIONS
55	Paris-Trousseau: evidence keeps pointing to FLI1. <i>Blood</i> , 2015, 126, 1973-1974.	1.4	5
56	Antiplatelet Effect of Ketorolac in Children After Congenital Cardiac Surgery. <i>World Journal for Pediatric &amp; Congenital Heart Surgery</i> , 2018, 9, 651-658.	0.8	5
57	Hypermethioninemia Leads to Fatal Bleeding and Increased Mortality in a Transgenic I278T Mouse Model of Homocystinuria. <i>Biomedicines</i> , 2020, 8, 244.	3.2	5
58	Diagnostic approach to the patient with a suspected inherited platelet disorder: Who and how to test. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2127-2136.	3.8	5
59	von Willebrand disease: proposing definitions for future research. <i>Blood Advances</i> , 2021, 5, 565-569.	5.2	5
60	Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1576-1588.	3.8	5
61	Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength. <i>Platelets</i> , 2022, 33, 1119-1131.	2.3	5
62	Product selection issues in the management of hemophilia B. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, S17-S18.	1.0	4
63	Genetic basis of congenital platelet disorders. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 337-342.	2.5	4
64	ETV6-related thrombocytopenia and platelet dysfunction. <i>Platelets</i> , 2021, 32, 141-143.	2.3	4
65	Evaluating Familial Essential Tremor with Novel Genetic Approaches: Is it a Genotyping or Phenotyping Issue?. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 258.	2.0	4
66	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. <i>Blood Advances</i> , 2022, 6, 420-428.	5.2	4
67	SHPing in different directions in platelet production. <i>Blood</i> , 2013, 121, 4018-4019.	1.4	2
68	Variable bleeding phenotype in an Amish pedigree with von Willebrand disease. <i>American Journal of Hematology</i> , 2016, 91, E431-5.	4.1	2
69	Negatively charged nanoparticles of multiple materials inhibit shear-induced platelet accumulation. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 35, 102405.	3.3	2
70	Genotypic and Phenotypic Analysis of Adolescents with Heavy Menstrual Bleeding and Low Von Willebrand Activity - Interim Report of a Multi-Center Study. <i>Blood</i> , 2018, 132, 984-984.	1.4	2
71	Epigenetic Profiles of Primary Endothelial Cells from Patients with Low VWF Levels. <i>Blood</i> , 2018, 132, 983-983.	1.4	2
72	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. <i>Blood</i> , 2018, 132, 979-979.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Rheumatoid Arthritis Causes Hematopoietic Stem Cell Reprogramming to Maintain Functionality. Blood, 2018, 132, 2573-2573.	1.4	1
74	PACAP: a new player in thrombopoiesis. Blood, 2008, 111, 1753-1754.	1.4	0
75	VWD type 1: a calculated diagnosis. Blood, 2008, 111, 3919-3920.	1.4	0
76	The ASPHO Meeting. Pediatric Blood and Cancer, 2011, 56, 974-974.	1.5	0
77	The ASPHO Meeting (25 Years of Excellence). Pediatric Blood and Cancer, 2012, 58, 1098-1098.	1.5	0
78	SNP Analysis Of The VWF GENE Identifies Multiple Common Variants THAT Affect VWF Levels and OCCUR At Different Frequencies In Patients With TYPE 1 VWD. Blood, 2013, 122, 334-334.	1.4	0
79	Novel Congenital Platelet Disorders. Blood, 2016, 128, SCI-39-SCI-39.	1.4	0
80	Single Cell RNA Sequencing of Blood Outgrowth Endothelial Cells from Patients with Low Von Willebrand Factor Reveal Multiple Novel Signaling Pathways. Blood, 2018, 132, 982-982.	1.4	0
81	Understanding congenital platelet disorders. Clinical Advances in Hematology and Oncology, 2014, 12, 461-3.	0.3	0